Revolution Medicines (RVMD) Capital Expenditures (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Capital Expenditures of $786000.0 for Q1 2026, down 71.78% year-over-year from $2.8 million in Q1 2025, and down 75.98% quarter-over-quarter from $3.3 million in Q4 2025.
Revolution Medicines (RVMD) Capital Expenditures (2019 - 2026) Analysis & Trends
Revolution Medicines' Capital Expenditures history runs 8 years deep, the most recent figure standing at $786000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 71.78% year-over-year to $786000.0; the TTM figure through Mar 2026 stood at $14.0 million (up 211.88% YoY), while the FY2025 annual figure was $16.0 million, up 914.59% from the prior year.
- Capital Expenditures for Q1 2026 stood at $786000.0, down from $3.3 million in the prior quarter.
- The five-year high for Capital Expenditures was $7.9 million in Q2 2025, with the low at -$7.5 million in Q4 2024.
- The 5-year median for Capital Expenditures is $1.3 million (2023), against an average of $1.4 million.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures tumbled 452.47% in 2023, then surged 2328.0% in 2025.
- Revolution Medicines' Capital Expenditures stood at -$507000.0 in 2022, then sank by 452.47% to -$2.8 million in 2023, then tumbled by 168.12% to -$7.5 million in 2024, then surged by 143.57% to $3.3 million in 2025, then slumped by 75.98% to $786000.0 in 2026.
- Business Quant data shows RVMD's Capital Expenditures at $786000.0 in Q1 2026, $3.3 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.29 Mn |
| Jun 30, 2026 | 2.29 Mn |
| Mar 31, 2026 | 786,000.00 |
| Mar 31, 2026 | 786,000.00 |
| Dec 31, 2025 | 3.27 Mn |
| Dec 31, 2025 | 3.27 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 7.93 Mn |
| Jun 30, 2025 | 7.93 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Mar 31, 2025 | 2.79 Mn |
| Dec 31, 2024 | -7.51 Mn |
| Dec 31, 2024 | -7.51 Mn |
| Sep 30, 2024 | 3.52 Mn |
| Sep 30, 2024 | 3.52 Mn |
| Jun 30, 2024 | 5.69 Mn |
| Jun 30, 2024 | 5.69 Mn |
| Mar 31, 2024 | -125,000.00 |
| Mar 31, 2024 | -125,000.00 |